LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Gene Mutations Found for Wilms Tumor

By LabMedica International staff writers
Posted on 18 Sep 2014
Image: The Agilent 2100 bioanalyzer system provides sizing, quantitation and quality control of DNA, RNA, proteins and cells on a single platform (Photo courtesy of Agilent Technologies).
Image: The Agilent 2100 bioanalyzer system provides sizing, quantitation and quality control of DNA, RNA, proteins and cells on a single platform (Photo courtesy of Agilent Technologies).
Image: Histopathology of a kidney showing the characteristic triphasic pattern consisting of tubules, solid sheets of small round cells, and stroma of a Wilms tumor (Photo courtesy of Nephron).
Image: Histopathology of a kidney showing the characteristic triphasic pattern consisting of tubules, solid sheets of small round cells, and stroma of a Wilms tumor (Photo courtesy of Nephron).
The genetic causes of Wilms tumor, a type of kidney cancer found only in children, has been revealed by whole-exome sequencing identifying missense mutations in the microRNA (miRNA)-processing enzymes.

Wilms tumor or nephroblastoma is the most common childhood genitourinary tract cancer and the third most common pediatric solid tumor and it comprises 95% of all renal cancers and 6% of all cancers diagnosed among children less than 15 years of age.

Scientists the University of Texas Southwestern Medical Center (Dallas, TX, USA) performed exome capture and massively parallel sequencing on a discovery set of 15 pairs of Wilms tumors and matched adjacent normal kidney cortices, and subsequently performed whole-exome sequencing on a validation set of 29 additional Wilms tumors. The team of scientists also performed cell culture and immunoprecipitation, small ribonucleic acid (RNA) sequencing.
.
Small RNAs were isolated from each tumor sample and all samples were analyzed using the RNA 6000 Nano LabChip (Agilent Technologies; Santa Clara, CA, USA) on an Agilent Technologies 2100 Bioanalyzer. Western blotting was performed using monoclonal antibodies and miRNA expression was analyzed in engineered cell lines. Libraries produced were sequenced using the HiSeq 2000 (Illumina; San Diego, CA, USA), producing 100 bp paired-end reads.

Examination of tumor miRNA expression, in vitro processing assays and genomic editing in human cells demonstrated that the gene mutations in endoribonuclease Dicer (DICER1) and ribonuclease 3 (DROSHA) influence miRNA processing through distinct mechanisms.

James F. Amatruda, MD, PhD, a Professor of Pediatrics, Molecular Biology, and Internal Medicine, and senior author of the study said, “The most common, and in some ways the most biologically interesting, mutations were found in genes called DROSHA and DICER1. We found that these mutations affected the cell's production of microRNAs, which are tiny RNA molecules that play big roles in controlling the growth of cells, and the primary effect was on a family of microRNAs called let-7. Let-7 is an important microRNA that slows cell growth and in Wilms tumors in which DROSHA or DICER1 were mutated, let-7 RNA is missing, which causes the cells to grow abnormally fast.” The study was published on September 5, 2014, in the journal Nature Communications.

Related Links:

University of Texas Southwestern Medical Center
Agilent Technologies 
Illumina 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Pipette
Accumax Smart Series

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more